Unicycive Capital Lease Obligations from 2010 to 2025
| UNCY Stock | USD 0.59 0 0.34% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 912 K | Current Value 957.5 K | Quarterly Volatility 354.5 K |
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.6 K, Net Interest Income of 493.9 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
Unicycive | Capital Lease Obligations |
Latest Unicycive Therapeutics' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Unicycive Therapeutics over the last few years. Unicycive Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Unicycive Therapeutics asset purchases. For example, Unicycive Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Unicycive Therapeutics control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Unicycive Therapeutics' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Unicycive Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 195,219 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 181.60 | |
| Mean Deviation | 273,453 | |
| Median | 0.00 | |
| Standard Deviation | 354,523 | |
| Sample Variance | 125.7B | |
| Range | 957.5K | |
| R-Value | 0.76 | |
| Mean Square Error | 56.9B | |
| R-Squared | 0.58 | |
| Significance | 0.0006 | |
| Slope | 56,586 | |
| Total Sum of Squares | 1.9T |
Unicycive Capital Lease Obligations History
About Unicycive Therapeutics Financial Statements
Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 912 K | 957.5 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.